Möchten Sie immer auf dem neuesten Stand bleiben?

PharmAla files its audited year end and unaudited Q1 financials.

Training supports multi-site clinical trial of MDMA-assisted Massed Prolonged Exposure Therapy for PTSD in active-duty service members.First-of-its-kind therapist preparation supports the Department...

PharmAla ships MDMA to Mt. Sinai Hospital and starts making patented novel MDMA-like drug, preparing for a phase 2 clinical trial into Social Anxiety.

PharmAla completes delivery of a Phase 3 clinical trial contract after finishing release testing on an australian-made batch of LaNeo MDMA.

PharmAla files its final short form prospectus, and announces a signed term sheet with an R&D tax credit financing firm called Radium

PharmAla launches new web portal for MDMA prescribers and appoints a new COO

MAPS brings MDMA-assisted therapy training to Poland for the first time, awarding scholarships to 20 practitioners from war-affected Ukraine and Palestine.

Backed by Sam Altman, Fred Ehrsam, and Dylan Field, Arcadia Medicine is accelerating development of safe empathogens via patented, non-racemic MDMA

PharmAla completes first domestic US shipment of MDMA from its new domestic distribution center, and issues shares as debt payment.

ATMA CENA announce the expansion of its psychedelic therapy clinic network to 13 locations across Canada